Central African Republic vs EMR: Hepatitis B surface antigen (HBsAg) prevalence
Central African Republic
5.3%
in 2024
EMR
0.5%
in 2024
Central African Republic rank
1st
EMR rank
4th
Hepatitis B surface antigen (HBsAg) prevalence over time
- Central African Republic
- EMR
How they compare
Central African Republic currently reports 5.3% against 0.5% in EMR, a difference of 4.8%.
That makes Central African Republic's figure about 10.6 times EMR's.
Across all 10 years both countries report, Central African Republic has been ahead every year.
Central African Republic ranks 1st and EMR ranks 4th of 194 countries.
Central African Republic has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Central African Republic | EMR | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 10.0% | 0.6% | 9.5% | Central African Republic |
| 2020s | 7.0% | 0.5% | 6.5% | Central African Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Central African Republic or EMR?
- Central African Republic, at 5.3% against 0.5% in EMR as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Central African Republic and EMR?
- 4.8%, with Central African Republic ahead.
- How many years of comparable data are there for Central African Republic and EMR?
- 10 years are reported by both, from 2015 to 2024.
- How do Central African Republic and EMR rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Central African Republic ranks 1st and EMR ranks 4th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.